Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price objective increased by Robert W. Baird from $32.00 to $40.00 in a research report sent to investors on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Trading Down 2.0 %

Shares of Enliven Therapeutics stock traded down $0.51 on Friday, reaching $24.41. The stock had a trading volume of 248,450 shares, compared to its average volume of 260,255. The business’s 50 day moving average is $26.28 and its two-hundred day moving average is $23.94. Enliven Therapeutics has a 1 year low of $9.80 and a 1 year high of $30.03. The company has a market cap of $1.15 billion, a P/E ratio of -12.85 and a beta of 1.08.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, equities analysts anticipate that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00. Following the transaction, the chief executive officer now directly owns 1,049,255 shares of the company’s stock, valued at approximately $24,017,446.95. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $22.54, for a total value of $95,795.00. The disclosure for this sale can be found here. Insiders sold a total of 152,195 shares of company stock worth $4,091,454 over the last three months. 29.20% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in ELVN. EntryPoint Capital LLC bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at about $167,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $2,020,000. Blackstone Inc. bought a new stake in Enliven Therapeutics during the 1st quarter valued at $443,000. Janus Henderson Group PLC boosted its position in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after buying an additional 305,397 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after buying an additional 37,632 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.